H Echizen
Impact in
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
- Drug-Induced Hepatotoxicity and Protection
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
Papers in
-
- Pharmacogenetics and Drug Metabolism 6
-
- Metabolism and Genetic Disorders 4
- Co-authors
- Michel EichelbaumTakashi IshizakiHarumi TakahashiElke SchmidtB. VogelgesangKazuhiro ChibaM TaniMarkus G. Manz
In The Last Decade
H Echizen
30 papers receiving 744 citations
Peers
Comparison fields: 5 of 91
- Pharmacology 385
- Oncology 248
- Pediatrics, Perinatology and Child Health 155
- Spectroscopy 126
- Pharmacology 117
Countries citing papers authored by H Echizen
This map shows the geographic impact of H Echizen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Echizen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Echizen more than expected).
Fields of papers citing papers by H Echizen
This network shows the impact of papers produced by H Echizen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Echizen. The network helps show where H Echizen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside H Echizen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 3 | |
| 2 | 2003 | 81 | |
| 3 | 2002 | 2 | |
| 4 | 2002 | 12 | |
| 5 | 2002 | 38 | |
| 6 | 1999 | 22 | |
| 7 | Metabolism of warfarin enantiomers in Japanese patients with different CYP2C9/2C19 genotypes. | 1998 | 2 |
| 8 | 1995 | 101 | |
| 9 | 1994 | 35 | |
| 10 | 1994 | 7 | |
| 11 | 1993 | 33 | |
| 12 | [Non-steroidal anti-inflammatory agent, phase I clinical trial with CN-100--single and repeated oral administration study]. | 1992 | 1 |
| 13 | 1992 | 73 | |
| 14 | 1991 | 7 | |
| 15 | 1990 | 5 | |
| 16 | 1990 | 7 | |
| 17 | 1989 | 3 | |
| 18 | 1988 | 61 | |
| 19 | 1987 | 7 | |
| 20 | 1982 | 34 |
About H Echizen
H Echizen is a scholar working on Pharmacology, Clinical Biochemistry, Nephrology, Biochemistry and Pediatrics, Perinatology and Child Health, having authored 30 papers that have together received 777 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (6 papers), Metabolism and Genetic Disorders (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Pharmacological Effects and Toxicity Studies (4 papers), Receptor Mechanisms and Signaling (4 papers), Pharmaceutical studies and practices (3 papers), Metabolomics and Mass Spectrometry Studies (2 papers) and Analytical Chemistry and Chromatography (2 papers). The work is most often cited by research in Pharmacology (385 citations), Oncology (248 citations), Pediatrics, Perinatology and Child Health (155 citations), Spectroscopy (126 citations) and Pharmacology (117 citations). H Echizen has collaborated with scholars based in Japan, Austria and India. Frequent co-authors include Michel Eichelbaum, Takashi Ishizaki, Harumi Takahashi, Elke Schmidt, B. Vogelgesang, Kazuhiro Chiba, M Tani, Markus G. Manz, Katsuhiko Yoshimoto and H. Heidemann. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Clinical Chemistry and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.